{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:43:22Z","timestamp":1784288602023,"version":"3.55.0"},"reference-count":7,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2004,2]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To quantify the transfer of risperidone and its active metabolite 9-hydroxyrisperidone into breast milk, estimate the amount the infant receives, measure infant plasma concentrations, and clinically assess the safety of breast feeding during maternal risperidone administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARIES<\/jats:title>\n                    <jats:p>The transfer of risperidone and 9-hydroxyrisperidone into milk was studied in 2 breast-feeding women and one woman with risperidone-induced galactorrhea. Plasma samples were available from 2 of the women and from both breast-fed infants. The milk\/plasma concentration ratio determined in 2 women was &lt;0.5 for both compounds. The calculated relative infant \u201cdoses\u201d were 2.3%, 2.8%, and 4.7% (as risperidone equivalents) of the maternal weight-adjusted doses. Risperidone and 9-hydroxyrisperidone were not detected in the plasma of the 2 breast-fed infants studied, and no adverse effects were noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Risperidone therapy is sometimes necessary in breast-feeding women, raising the issue of safety in the exposed infants. Our study shows that the relative infant dose is lower than the arbitrary 10% level of concern. The data provide clear guidance on infant exposure for the cases presented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Maternal risperidone therapy is unlikely to be a significant hazard for the breast-fed infant in the short term. Nevertheless, decisions on whether a woman may breast-feed should be made as an individual risk-benefit analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1d326","type":"journal-article","created":{"date-parts":[[2004,1,12]],"date-time":"2004-01-12T12:02:56Z","timestamp":1073908976000},"page":"273-276","source":"Crossref","is-referenced-by-count":69,"title":["Transfer of Risperidone and 9-Hydroxyrisperidone into Human Milk"],"prefix":"10.1177","volume":"38","author":[{"given":"Kenneth F","family":"Ilett","sequence":"first","affiliation":[{"name":"Kenneth F Ilett PhD, Associate Professor of Pharmacology, Pharmacology Unit, School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L Peter","family":"Hackett","sequence":"additional","affiliation":[{"name":"L Peter Hackett MRSC, Research Scientist, Clinical Pharmacology and Toxicology Laboratory, The Western Australian Centre for Pathology & Medical Research, Nedlands, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith H","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Judith H Kristensen BPharm, Senior Pharmacist, Pharmacy Department, King Edward Memorial and Princess Margaret Hospitals, Women's and Children's Health Service, Subiaco, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna S","family":"Vaddadi","sequence":"additional","affiliation":[{"name":"Krishna S Vaddadi FRANZCP, Associate Professor in Psychiatry, Department of Psychological Medicine, Monash University, Clayton, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J","family":"Gardiner","sequence":"additional","affiliation":[{"name":"Sharon J Gardiner MClinPharm, Chief Drug Information Pharmacist, Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J","family":"Begg","sequence":"additional","affiliation":[{"name":"Evan J Begg MD, Professor of Medicine\/Clinical Pharmacology, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2004,2,1]]},"reference":[{"issue":"4","key":"bibr1-aph.1D326","first-page":"42","volume":"63","author":"Ernst CL","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"bibr2-aph.1D326","volume-title":"Risperdal (risperidone). E-MIMS Version 4.00.0062","author":"MIMS abbreviated prescribing information.","year":"2003"},{"key":"bibr3-aph.1D326","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200306000-00006"},{"key":"bibr4-aph.1D326","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200004000-00036"},{"key":"bibr5-aph.1D326","doi-asserted-by":"publisher","DOI":"10.1016\/B978-044481981-9\/50025-4"},{"key":"bibr6-aph.1D326","doi-asserted-by":"publisher","DOI":"10.1177\/089033402237904"},{"key":"bibr7-aph.1D326","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0114c"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D326","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1D326","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:36Z","timestamp":1777374516000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1D326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["10.1345\/aph.1D326"],"URL":"https:\/\/doi.org\/10.1345\/aph.1d326","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}